Lantheus $LNTH (+2,29%) has undergone a decisive transformation over the last 12 months to become a broad-based radiopharmaceutical player. With a growing pipeline, strategic acquisitions and strong cash flow, the starting position in 2025 is promising - even if margins have been slowed and guidance reduced in the short term. In the long term, significantly accelerated growth can be expected from 2026.

Strong growth, but declining margins - due to expenditure on acquisitions, R&D and shifts in the business model.

For me, the company remains a clear buy and I would like to increase my stake to 150 - 200 shares this year.

Acquisitions and portfolio structure in the last 12 months:

1. acquisition of global rights to NAV-4694 and RM2 (LNTH-2401/2402) - expansion in Alzheimer's & prostate cancer

2. life molecular imaging

3. evergreen Theragnostics

4. sale of the SPECT business (TechneLite, Neurolite, Cardiolite etc.) to Illuminated/SHINE

Massive investment in R&D (+116 % in 2024) to expand the portfolio.

Guidance 2025:

Sales USD 1.545-1.610 bn,

Non-GAAP EPS USD 7.00-7.20 (February).

In the current Q1 call, EPS guidance was lowered to USD 6.60-6.70 and sales slightly narrowed (USD 1.550-1.585 bn)

$PTP (-2,27%) Pentixapharm,

What exactly is the company that was spun off from Eckert and Ziegler? $EUZ (+1,61%) was spun off?

Andreas Eckert - founder of Eckert on this:

4 active ingredients including 2 in phase III and 2 in I/IIa

Target 2027 to bring both phase III diagnostics to market with EUR 55m expenditure.

However, further financing measures are required here.

20.8 million shares + 3.9 million in free float.

Other competitors in the market are

Telix Pharma and $TLX (-1,57%)

Lantheus Holding $LNTH (+2,29%)

New addition to the depot

$LNTH (+2,29%)
Lantheus Holdings

EUR 6.59 bn market cap

P/E RATIO 18

2-digit earnings growth forecast for the coming years

Broadly speaking, the company is involved in radiopharmaceutical oncology and precision diagnostics, etc.

The radiopharmaceutical oncology products support medical professionals in detecting, combating and monitoring cancer.

Dis precision diagnostics products help healthcare professionals detect and track diseases at an early stage - when it matters most.

In addition to diagnostic products, there are also therapeutic products and some in the pipeline.

Many of you will come into contact with the products at an older age (although I wouldn't wish it on anyone). Be it because of prostate cancer or to visualize the coronary arteries during a check-up.